Log In
Print
BCIQ
Print
Print this Print this
 

volociximab (M200)

Also known as: Anti-a5B1

  Manage Alerts
Collapse Summary General Information
Company Abbott Laboratories
DescriptionAntibody against integrin alpha(5)beta(1)
Molecular Target Integrin alpha(5)beta(1)
Mechanism of ActionAntibody
Latest Stage of DevelopmentPhase I
IndicationNon-small cell lung cancer (NSCLC)
Partner

Biogen Idec Inc.
 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today